AI stocks benefit from Trump-era tariffs and onshoring, while Relay Therapeutics and OPEX report corporate updates.
2 reports, 1 independent
Updated Aug 26
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AI stocks benefit from Trump-era tariffs and onshoring, while Relay Therapeutics and OPEX report corporate updates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Relay Therapeutics
company in Cambridge, United States
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- AI stocks are benefiting from Trump-era tariffs, with Morningstar and ClearBridge providing market analysis on growth and upside potential.
- Goldman Sachs and Zeta Interactive noted that tariffs and onshoring benefit AI stocks, citing accelerated Q2 growth and raising price targets.
- Barclays raised its price target for Okta, noting that AI stocks are benefiting from the onshoring trend and Trump-era tariffs.
- SharpLink Gaming acquired Ethereum above market prices, causing a stock price drop, while Trump tariffs continue to benefit AI stocks.
- Trump tariffs and onshoring benefit AI stocks, leading to automation and robotics support agreements involving Amazon and Richtech Robotics.
Coverage
Newest first; wire copies grouped- Insider MonkeyLeerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PT Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the top strong buy stocks under $5 to buy now. Leerink Partners an
- Unknown outlet